# | Title | Journal | Year | Citations |
---|
1 | Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial | Lancet Respiratory Medicine,the | 2021 | 277 |
2 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial | Journal of Thoracic Oncology | 2019 | 260 |
3 | Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer | Oncotarget | 2015 | 144 |
4 | Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer | Journal of Thoracic Oncology | 2015 | 105 |
5 | Prognostic Significance of Neutrophil Lymphocyte Ratio in Patients with Gastric Cancer: A Meta-Analysis | PLoS ONE | 2014 | 85 |
6 | Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients | Clinical Cancer Research | 2018 | 82 |
7 | T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients | Lung Cancer | 2014 | 81 |
8 | Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer | Oncology Reports | 2015 | 80 |
9 | Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy | Clinical Cancer Research | 2021 | 79 |
10 | Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma | Oncotarget | 2017 | 70 |
11 | Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients | Translational Oncology | 2014 | 68 |
12 | Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF | Cancer Medicine | 2019 | 59 |
13 | Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer | Journal of Thoracic Oncology | 2015 | 55 |
14 | Long non-coding RNA UCA1 promotes lung cancer cell proliferation and migration via microRNA-193a/HMGB1 axis | Biochemical and Biophysical Research Communications | 2018 | 55 |
15 | Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis | BMC Cancer | 2018 | 53 |
16 | Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma | Cell Biochemistry and Biophysics | 2012 | 52 |
17 | Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis | Asian Journal of Andrology | 2014 | 51 |
18 | Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics | Clinical and Translational Oncology | 2015 | 39 |
19 | Current progress and mechanisms of bone metastasis in lung cancer: a narrative review | Translational Lung Cancer Research | 2021 | 39 |
20 | Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma | Cancer Science | 2020 | 38 |
21 | Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial | Annals of Oncology | 2019 | 37 |
22 | Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer | Oncotarget | 2017 | 35 |
23 | High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients | Cancer Investigation | 2010 | 34 |
24 | Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy | Lung Cancer | 2012 | 34 |
25 | A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer | Gastric Cancer | 2018 | 33 |
26 | STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells | Frontiers in Oncology | 2019 | 33 |
27 | SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells | Oncotarget | 2017 | 33 |
28 | Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non‐small‐cell lung cancer | Histopathology | 2015 | 32 |
29 | Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma | Oxidative Medicine and Cellular Longevity | 2020 | 32 |
30 | A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene | Lung Cancer | 2013 | 31 |
31 | JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway | Oncology Reports | 2015 | 29 |
32 | Enhanced immunofluorescence detection of a protein marker using a PAA modified ZnO nanorod array-based microfluidic device | Nanoscale | 2018 | 28 |
33 | Current small cell lung cancer treatment in China | Thoracic Cancer | 2015 | 26 |
34 | Targeting STAT3 enhances NDV‐induced immunogenic cell death in prostate cancer cells | Journal of Cellular and Molecular Medicine | 2020 | 24 |
35 | HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition | Lung Cancer | 2020 | 21 |
36 | Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients | Clinical and Translational Oncology | 2012 | 20 |
37 | The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis | Biomarkers | 2014 | 20 |
38 | A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma | Drug Design, Development and Therapy | 2015 | 20 |
39 | αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib | | 2021 | 20 |
40 | Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer | Lung Cancer | 2022 | 19 |
41 | Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy | Frontiers in Immunology | 2022 | 19 |
42 | Mechanisms Behind the Inhibition of Lung Adenocarcinoma Cell by Shikonin | Cell Biochemistry and Biophysics | 2014 | 18 |
43 | Blood α-Tocopherol, γ-Tocopherol Levels and Risk of Prostate Cancer: A Meta-Analysis of Prospective Studies | PLoS ONE | 2014 | 18 |
44 | A Renal‐Clearable Activatable Molecular Probe for Fluoro‐Photacoustic and Radioactive Imaging of Cancer Biomarkers | Small | 2022 | 18 |
45 | The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer | Translational Lung Cancer Research | 2020 | 17 |
46 | Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer | Oncologist | 2020 | 17 |
47 | Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis | PLoS ONE | 2014 | 16 |
48 | AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS) | Annals of Oncology | 2018 | 14 |
49 | CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma | Genomics, Proteomics and Bioinformatics | 2020 | 14 |
50 | The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis | Frontiers in Oncology | 2021 | 14 |